CD19 and CD22 targeted CAR-T cell Therapy (Chongqing Precision Biotechnology)

N/A

Report date: 2024/08/06 11:09:34

Base Information

Drug NameCD19 and CD22 targeted CAR-T cell Therapy (Chongqing Precision Biotechnology)
Drug Alias NameAnti-CD19 anti-CD 22 chimeric antigen receptor T cell therapy (Chongqing Precision Biotechnology)Anti-CD19/Anti-CD22 CAR-T cell therapy (Chongqing Precision Biotechnology)CD19/CD22 dual CAR-T (Chongqing Precision Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChongqing Precision Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Precision Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A